Hisse Senetlerindeki Sıralama
#41904
Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition,... Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition, advancement, and commercialization of various pharmaceutical and biotechnology solutions. A pivotal focus lies on Lodonal, their lead investigational drug candidate, designed as a once-daily immune system modulator aimed at managing both human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Beyond this primary drug, their portfolio encompasses several innovative programs. These include a Global Telehealth platform and an early-stage Medtech initiative leveraging blockchain and smart contract technologies to enhance the security and management of prescriptions and electronic health records. Furthermore, Biostax is developing JKB-122, an experimental small molecule that acts as a long-duration toll-like receptor 4 (TLR4) antagonist, intended for the treatment of autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). Another compound they address is Low Dose Naltrexone, a formula believed to offer immune-modulating advantages pertinent to conditions such as cancer, chronic pain, autoimmune disorders, and anti-aging efforts. The company also pursues development efforts for addressing hyperphosphatemia. Biostax maintains a licensing agreement with Cytocom Inc. and underwent a corporate name change from Immune Therapeutics, Inc. to its current designation in October 2023. The company's operational base is located in Winter Park, Florida.
Hisse Fiyatı
$0.0001
Son senkronizasyon: 2026-08-11
Ticaret Biostax Corp. (BTAX)
Biostax Corp. (BTAX) için kazanç
2026 itibarıyla kazanç TTM: 0
Biostax Corp. şirketinin en son finansal raporlarına göre, mevcut kazancı 0'dir. 2026 yılında şirket 0 kazanç elde etti, bu 2026 yılındaki 0 kazanca göre önceki yıla eşit. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Biostax Corp. için kazanç geçmişi 2026 - 2026
Her yılın sonundaki kazanç
| Yıl |
Kazanç |
Değiştir |
|
Sağlanan tarihler için yeterli veri yok. |
Benzer şirketler veya rakipler için kazanç
| Şirket |
Kazanç |
Kazanç Farkı |
Ülke |
|
|
$5.27B |
-
|
US
|
|
|
$1.95B |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
$3.01B |
-
|
BE
|
|
|
- |
-
|
KR
|